These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 10029591)

  • 1. Labeling of the internal pool of GP IIb-IIIa in platelets by c7E3 Fab fragments (abciximab): flow and endocytic mechanisms contribute to the transport.
    Nurden P; Poujol C; Durrieu-Jais C; Winckler J; Combrié R; Macchi L; Bihour C; Wagner C; Jordan R; Nurden AT
    Blood; 1999 Mar; 93(5):1622-33. PubMed ID: 10029591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors.
    Peter K; Schwarz M; Ylänne J; Kohler B; Moser M; Nordt T; Salbach P; Kübler W; Bode C
    Blood; 1998 Nov; 92(9):3240-9. PubMed ID: 9787160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
    Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of markers of platelet activation and the interpatient variation in response to abciximab.
    Bihour C; Durrieu-Jaïs C; Macchi L; Poujol C; Coste P; Besse P; Nurden P; Nurden AT
    Arterioscler Thromb Vasc Biol; 1999 Feb; 19(2):212-9. PubMed ID: 9974400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors.
    Kleiman NS; Raizner AE; Jordan R; Wang AL; Norton D; Mace KF; Joshi A; Coller BS; Weisman HF
    J Am Coll Cardiol; 1995 Dec; 26(7):1665-71. PubMed ID: 7594101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of c7E3 Fab on thrombus formation and rt-PA-Mediated thrombolysis under flow conditions.
    Huang TC; Jordan RE; Hantgan RR; Alevriadou BR
    Thromb Res; 2001 Jun; 102(5):411-25. PubMed ID: 11395127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade.
    Coller BS; Lang D; Scudder LE
    Circulation; 1997 Feb; 95(4):860-7. PubMed ID: 9054743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical role of platelet glycoprotein IIb/IIIa receptor inhibitors in ischemic heart disease.
    Lefkovits J; Topol EJ
    Cleve Clin J Med; 1996; 63(3):181-9. PubMed ID: 8665658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time.
    Ammar T; Scudder LE; Coller BS
    Circulation; 1997 Feb; 95(3):614-7. PubMed ID: 9024148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty.
    Konstantopoulos K; Kamat SG; Schafer AI; Bañez EI; Jordan R; Kleiman NS; Hellums JD
    Circulation; 1995 Mar; 91(5):1427-31. PubMed ID: 7867183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. c7E3 Fab inhibits low shear flow modulated platelet adhesion to endothelium and surface-absorbed fibrinogen by blocking platelet GP IIb/IIIa as well as endothelial vitronectin receptor--results from patients with acute myocardial infarction and healthy controls.
    Reininger AJ; Agneskirchner J; Bode PA; Spannagl M; Wurzinger LJ
    Thromb Haemost; 2000 Feb; 83(2):217-23. PubMed ID: 10739376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The glycoprotein IIb/IIIa antagonist c7E3 inhibits platelet aggregation in the presence of heparin-associated antibodies.
    Liem TK; Teel R; Shukla S; Silver D
    J Vasc Surg; 1997 Jan; 25(1):124-30. PubMed ID: 9013915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy.
    Mascelli MA; Worley S; Veriabo NJ; Lance ET; Mack S; Schaible T; Weisman HF; Jordan RE
    Circulation; 1997 Dec; 96(11):3860-6. PubMed ID: 9403608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa.
    Turner NA; Moake JL; Kamat SG; Schafer AI; Kleiman NS; Jordan R; McIntire LV
    Circulation; 1995 Mar; 91(5):1354-62. PubMed ID: 7867173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade.
    Ghaffari S; Kereiakes DJ; Lincoff AM; Kelly TA; Timmis GC; Kleiman NS; Ferguson JJ; Miller DP; Califf RA; Topol EJ
    Am J Cardiol; 1998 Jul; 82(1):7-12. PubMed ID: 9671000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
    Rossi F; Rossi E; Pareti FI; Colli S; Tremoli E; Gallo L
    Haematologica; 2001 Feb; 86(2):192-8. PubMed ID: 11224490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa.
    Schneider DJ; Taatjes DJ; Sobel BE
    Cardiovasc Res; 2000 Jan; 45(2):437-46. PubMed ID: 10728364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative antiplatelet efficacy of a novel, nonpeptide GPIIb/IIIa antagonist (XV454) and abciximab (c7E3) in flow models of thrombosis.
    Abulencia JP; Tien N; McCarty OJ; Plymire D; Mousa SA; Konstantopoulos K
    Arterioscler Thromb Vasc Biol; 2001 Jan; 21(1):149-56. PubMed ID: 11145947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New antiplatelet agents: platelet GPIIb/IIIa antagonists.
    Coller BS; Anderson K; Weisman HF
    Thromb Haemost; 1995 Jul; 74(1):302-8. PubMed ID: 8578476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
    Dyke CM
    Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.